Free Trial
→ A Worldwide Gold Lockdown Is Now Underway (From Stansberry Research) (Ad)tc pixel

Design Therapeutics (NASDAQ:DSGN) Earns Sell (D-) Rating from Weiss Ratings

Written by MarketBeat
October 25, 2025
Design Therapeutics logo with Medical background

Key Points

  • Design Therapeutics has been assigned a "sell (D-)" rating by Weiss Ratings, indicating negative sentiment towards the stock's performance.
  • Despite the poor rating, shares of Design Therapeutics saw a slight increase of 0.5%, closing at $5.73 with a market cap of $326.32 million.
  • Institutional investors hold 56.64% of the company's stock, with significant stakes being added by hedge funds like Nuveen LLC and American Century Companies Inc. in recent quarters.
  • Interested in Design Therapeutics? Here are five stocks we like better.

Design Therapeutics (NASDAQ:DSGN - Get Free Report)'s stock had its "sell (d-)" rating reaffirmed by equities researchers at Weiss Ratings in a research report issued on Friday,Weiss Ratings reports.

Design Therapeutics Stock Up 0.5%

Shares of DSGN traded up $0.03 during mid-day trading on Friday, hitting $5.73. 86,493 shares of the company's stock were exchanged, compared to its average volume of 202,881. Design Therapeutics has a 52 week low of $2.60 and a 52 week high of $7.77. The stock's 50-day simple moving average is $6.03 and its 200-day simple moving average is $4.63. The firm has a market cap of $326.32 million, a price-to-earnings ratio of -5.12 and a beta of 1.68.

Design Therapeutics (NASDAQ:DSGN - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.02). Analysts forecast that Design Therapeutics will post -0.91 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in DSGN. Nuveen LLC bought a new position in Design Therapeutics in the first quarter valued at approximately $568,000. American Century Companies Inc. increased its stake in Design Therapeutics by 13.5% in the first quarter. American Century Companies Inc. now owns 44,415 shares of the company's stock valued at $171,000 after acquiring an additional 5,300 shares during the last quarter. Wellington Management Group LLP bought a new position in Design Therapeutics in the first quarter valued at approximately $546,000. Driehaus Capital Management LLC increased its stake in Design Therapeutics by 17.7% in the first quarter. Driehaus Capital Management LLC now owns 913,399 shares of the company's stock valued at $3,526,000 after acquiring an additional 137,317 shares during the last quarter. Finally, Velan Capital Investment Management LP bought a new position in Design Therapeutics in the first quarter valued at approximately $54,000. 56.64% of the stock is owned by institutional investors.

Design Therapeutics Company Profile

(Get Free Report)

Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.

Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Design Therapeutics Right Now?

Before you consider Design Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Design Therapeutics wasn't on the list.

While Design Therapeutics currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Ride The A.I. Megaboom Cover
7 Stocks to Ride The A.I. Megaboom


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report
Like this article? Share it with a colleague.